CD19 CAR-T cells

BIOLOGICAL14 trials

Sponsors

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, Tianjin Mycure Medical Technology Co., Ltd, National University of Malaysia, Chongqing Precision Biotech Co., Ltd, Zhejiang University

Conditions

ALLAcute Lymphoblastic LeukemiaAutoimmune DiseasesB-cell Acute Lymphoblastic LeukemiaB-cell Acute Lymphocytic LeukemiaCD19 PositiveLarge B-Cell Lymphoma (LBCL)Leukemia

Phase 1

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdB-cell Acute Lymphocytic Leukemia

Start: 2017-03-01End: 2025-12-31Target: 10Updated: 2023-11-29

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdAcute Lymphoblastic Leukemia, CD19 Positive, Refractory +1

Start: 2017-07-01End: 2025-12-31Target: 40Updated: 2024-05-28

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Tianjin Mycure Medical Technology Co., LtdB-cell Acute Lymphoblastic Leukemia

Start: 2018-09-07End: 2021-01-01Target: 18Updated: 2018-09-14

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., LtdLeukemia, Leukemia, B-cell, Leukemia, Lymphocytic, Chronic, B-Cell +2

Start: 2019-06-01End: 2024-07-01Target: 80Updated: 2023-04-18

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Chongqing Precision Biotech Co., LtdLeukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell +1

Start: 2019-12-01End: 2024-07-01Target: 40Updated: 2023-04-18

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

RecruitingNCT06585514

Beijing GoBroad HospitalLupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)

Start: 2024-10-17End: 2026-12-31Target: 18Updated: 2026-03-10

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

RecruitingNCT06688799

Beijing GoBroad HospitalAutoimmune Diseases

Start: 2024-11-23End: 2026-12-01Target: 18Updated: 2026-03-10

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

RecruitingNCT06710717

National University of MalaysiaSystemic Lupus Erythematous (SLE)

Start: 2025-01-03End: 2029-01-02Target: 5Updated: 2025-05-29

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Not yet recruitingNCT07161193

Hebei Senlang Biotechnology Inc., Ltd.Autoimmune Diseases

Start: 2025-09-30End: 2027-11-18Target: 30Updated: 2025-09-08

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

RecruitingNCT07233642

The Children's Hospital of Zhejiang University School of MedicineSystemic Lupus Erythematosus

Start: 2025-11-30End: 2028-09-30Target: 18Updated: 2025-11-18

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

RecruitingNCT07331467

Chongqing Precision Biotech Co., LtdSystemic Lupus Erythematosus

Start: 2026-01-31End: 2028-08-31Target: 18Updated: 2026-01-12

Phase 2

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

RecruitingNCT03937544

National University of MalaysiaRefractory B Acute Lymphoblastic Leukaemia, Relapsed B Acute Lymphoblastic Leukaemia

Start: 2019-03-19End: 2027-03-18Target: 10Updated: 2025-05-29

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

RecruitingNCT04661020

Zhejiang UniversityLarge B-Cell Lymphoma (LBCL)

Start: 2020-12-03End: 2026-12-20Target: 40Updated: 2026-04-07

A Multicenter Study of CAR-T Cells in Primary Ph+All

RecruitingNCT07252336

Zhejiang UniversityALL

Start: 2025-11-30End: 2028-11-30Target: 50Updated: 2025-12-04

Related Papers

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations

Journal of Translational Medicine2026-03-30

Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.

Journal of Clinical Oncology2023-06-01

Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.

Journal of Clinical Oncology2023-06-01

CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL.

2023-02-156 citations

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with <i> <i>BCR::ABL1</i> </i>-like Acute Lymphoblastic Leukemia

Blood2022-11-15

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy

Frontiers in Immunology2022-08-2917 citations

Autologous CD19-directed CAR T cells produced by novel PrimeCARmanufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed/refractory B-lineage acute leukemia (r/r B-ALL).

Journal of Clinical Oncology2022-06-011 citations

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy

Blood2021-11-053 citations

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

2021-08-0736 citations

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2020-11-044 citations

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia.

2020-07-3125 citations

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood2019-11-134 citations